BioCryst Pharmaceuticals | BCRX - Umsatzkosten





Umsatzkosten Veränderung Datum
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
BioCryst Pharmaceuticals USD 3.84M 5.68M 2026-06
Chugai Pharma JPY 104.22B 11.43B 2026-06
Daiichi Sankyo JPY 124.29B 6.02B 2026-06
Gilead Sciences USD 1000M 445M 2026-06
GlaxoSmithKline GBP 2.07B 192M 2026-06
Glaxosmithkline GBP 1.88B 1.6B 2026-03
Incyte USD 104.96M 457K 2026-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
Karyopharm Therapeutics USD 1.34M 139K 2026-03
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Novavax USD 22.1M 608K 2025-12
PTC Therapeutics USD 39.61M 23.31M 2026-03
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Roche Holding CHF 7.85B 630M 2026-06
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06